Skip to content

Exagen Inc. XGN Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
Vor Biopharma logo
Vor BiopharmaVOR
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
CareDx logo
CareDxCDNA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s operating lease right-of-use assets in other assets?
Exagen Inc. (XGN) reported operating lease right-of-use assets in other assets of $1.18M in Q1 2026.
How has Exagen Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
Exagen Inc.'s operating lease right-of-use assets in other assets decreased by 45.6% year-over-year, from $2.17M to $1.18M.